SecBot SecBot
PRESS-RELEASE ·Filed May 18, 2026

REGN

Regeneron Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

This is a small, early-stage R&D collaboration for a mega-cap biotech, no near-term revenue or earnings impact. Monitor for future milestone announcements or clinical data readouts on AHC candidates, but no immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$629.34
T+0 close · May 18, 2026 · via day close
Latest settled
+26.80%
T+60 · $797.99
Vs SPY
+22.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $629.34entry
  2. T+1 · 6mo ago +0.07%α +0.72% · $629.76
  3. T+5 · 6mo ago +0.45%α −1.17% · $632.17
  4. T+20 · 5mo ago −2.28%α −4.47% · $614.98
  5. T+60 · 3mo ago +26.80%α +22.22% · $797.99

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Regeneron announced a strategic research collaboration with Parabilis Medicines to discover Antibody-Helicon Conjugates (AHCs) targeting previously undruggable intracellular proteins. Regeneron will pay Parabilis $125M upfront ($50M cash + $75M equity commitment), with up to ~$2.2B in additional milestone payments plus tiered royalties. The deal is a modest R&D bet for a $73B biotech, the upfront is ~0.17% of market cap, but opens a novel therapeutic modality.

Key Financial Metrics

Deal Value
$125.0M

Key Facts

  • Regeneron pays $125M to Parabilis: $50M upfront + $75M equity commitment
  • Up to ~$2.2B in total milestone payments plus tiered royalties up to low double-digits
  • Collaboration focuses on Antibody-Helicon Conjugates (AHCs) for intracellular targets
  • Five initial targets with option to add more upon additional option payments
  • Regeneron responsible for development, manufacturing, and worldwide commercialization

Financial Impact

Upfront cost of $125M (~0.17% of REGN's $73.2B market cap); total deal value up to ~$2.2B in milestones, but these are contingent and distant

r&d_expensecash

Risk Factors

  • Helicon platform is unproven in humans; AHCs are a novel modality with high technical risk
  • Milestone payments are contingent on development success, most early-stage collaborations never reach commercialization
  • No change to Regeneron's core revenue drivers (Eylea, Dupixent, Libtayo)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3296473

Track record

53 reports on REGN

Performance horizon

11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (10h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026